← Leaderboards
Batsheva Kerem
San Diego Biomedical Research Institute
$1,048,799
Attributed
$2,097,597
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $580.7K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,097,597 · 1
By mechanism
R01$2,097,597 · 1
Top collaborators
- David M Gilbert5 shared
Others in their field
Other Rising Stars on “Affect”
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Thomas K Karikari · Wake Forest University Health Sciences$14,340,584
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Brian Todd Schaneberg · Illinois Institute Of Technology$13,469,813
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
Research focus
AffectGenetic TranscriptionAphidicolinAppearanceArchitectureCancer BiologyCancer DiagnosisCancer TherapyCancer TypeCcne1 GeneCell Culture TechniquesCellsChimeric ProteinsChromosomal BreaksChromosome Fragile SitesChromosomesClinically RelevantComplexCultured CellsDna SequenceDruggable TargetEvolutionFrequenciesGenomic Instability
Grant awards (5)
Oncogenic pathway-induced fragile sites: a new paradigm for understanding genome instability in cancer$400,436
R01 · FY2025 · CA
Oncogenic pathway-induced fragile sites: a new paradigm for understanding genome instability in cancer$119,247
R01 · FY2025 · CA
Oncogenic pathway-induced fragile sites: a new paradigm for understanding genome instability in cancer$492,376
R01 · FY2024 · CA
Oncogenic pathway-induced fragile sites: a new paradigm for understanding genome instability in cancer$504,860
R01 · FY2023 · CA
Oncogenic pathway-induced fragile sites: a new paradigm for understanding genome instability in cancer$580,678
R01 · FY2022 · CA